Carmine Therapeutics And Takeda Pharmaceuticals Join Hands In A US$900M Research Alliance

Carmine Therapeutics and Takeda will collaborate to discover and develop non-viral Rare Disease Gene Therapies Using Carmine’s novel REGENT platform

U.S. headquartered Biotech startup Carmine Therapeutics has signed a $900 million research collaboration agreement with Takeda Pharmaceutical to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets, according to a company statement released on Tuesday.

Japanese multinational pharmaceutical and biopharmaceutical company Takeda has also committed a $5M convertible loan to support the development of Carmine’s novel REGENT platform.

According to the terms of the agreement, Takeda will provide an undisclosed amount as upfront payment to Carmine, offer research funding support, and over $900 million in total milestone payments in addition to tiered royalties.

Carmine has raised over $9.4 million in seed funding in an oversubscribed round led by Esco Ventures from Esco Ventures and Takeda Ventures, since its inception in August 2019.

Takeda can choose to license the programs developed by Carmine after the completion of pre-clinical proof-of-concept studies, and would be responsible for clinical development and commercialization, according to the statement.

The 10-month-old startup was founded by Esco Ventures X, serial biotech entrepreneur and MIT Professor Harvey Lodish, who is also the Chair of the Scientific Advisory Board of Carmine, and Professors Minh Le and Jiahai Shi.

The startup was incubated in Singapore by Esco Venture, the corporate venture and incubation arm of Esco Group. The startup is heaquartered in Cambridge, Massachusetts with its research arm based in Singapore.

Managing Partner of Esco Ventures and Founder and CEO of Carmine Therapeutics Lin Xiang Qian said, “This collaboration leverages Takeda’s industry leading rare diseases expertise and resources, and Carmine’s REGENT platform, to bring transformative non-viral gene therapies to patients.”

The latest funding will allow Carmine to further develop its REGENT platform, and advance its wholly-owned programs, he added.

According to the statement, Carmine is a new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs) as allogeneic therapies.

The new technology leverages RBCEVs to deliver nucleic acid payloads using extracellular vesicles, which is a natural way to transfer information between cells. The startup is currently focussing on non-viral gene therapies.

Developed by Le at the National University of Singapore and Shi Jiahai at the City University of Hong Kong, the foundation work for this novel technology was first published in Nature Communications in 2018, and aims to revolutionize nucleic acid therapies.

RBCEV-based gene therapy has the potential for repeat dosage, can be externally engineered, at scale, to carry large nucleic acid payloads of at least 11 kilobases, and surface functionalized with targeting ligands to increase bioavailability in specific tissues and cell types.

Takeda Rare Diseases Drug Discovery Unit Head Madhu Natarajan said, “At Takeda, we’re expanding our foundation in gene therapy by establishing a network of innovative partners like Carmine Therapeutics who are pursuing non-viral vector approaches that could leapfrog today’s technology.”

“Developing alternative gene therapy delivery vehicles like the REGENT platform that could address the challenges of AAV gene therapy is critical to one day delivering next-generation cures for rare diseases,” he added.

Takeda has also entered into a strategic partnership with Sandiego-headquartered biopharmaceutical company Neurocrine Biosciences, which develops treatments for nerve and endocrine-related diseases and disorders, according to a report by Global Legal Chronicle.

Header Image courtesy of Carmine Therapeutics

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

Amazon vs Flipkart Who Will Win Festival Sale War in India

Amazon vs. Flipkart: Who Will Win the Big Festival Sale War in India?

Amazon India and Flipkart, the two biggest ecommerce giants in India, have always been in a neck-to-neck competition for supremacy in the country. There is no better occasion to showcase their strength and take advantage of people’s shopping mood than during the Indian festive season, which begins in late September featuring various festivals, like Durga Pooja, Dussehra and Diwali.

Reviewing Top AI Boyfriends on Google Play Store

Anima vs. Replika: Reviewing Top AI Boyfriends on Google Play Store

Finding your perfect match can be a long and tedious process. You can go on date after date and still have a long way to go before you find your soulmate. In the meantime, you can curb your loneliness by speaking to an artificial intelligence (AI) chatbot.There are dozens of AI chatbots on the market today that give you the experience of having someone to vent your issues to and discuss your daily lives with.

Shrinkflation

What Is “Shrinkflation” and Why Opting For It Isn’t Companies’ Only Choice

You might have noticed grocery prices are soaring, or your usual go-to pack of chips is shrinking in size—all thanks to massive inflation. As of August 2022, the U.S. consumer price index (CPI), which measures the change in consumer prices for a specific set of goods over a period, has increased by 8.3% (year-on-year). Although it has gone down slightly from 8.6% in May, the highest it has ever been since 1981, it remains high and worrying.

Top 3 Affordable and Little-Known Smartphones to Bring Home in 2022

Top 3 Affordable and Little-Known Smartphones to Bring Home in 2022

Apple has remained at the center of the smartphone industry for years. The sleek, striking design, ever-improving chip and robust camera system of the iPhone have made it one of the most sought-after smartphones in the world. This month, Apple cemented and extended its lead in the industry by putting forward the next generation of iPhones.

5 More Business Podcasts You Need to Listen To

5 More Business Podcasts You Need to Listen To

Entrepreneurs have one thing in common—they always look for opportunities to learn and grow. To gain an understanding of running a viable business, you need to listen to the experiences of those who have emerged triumphant in the business world. A great way to do so is by tuning into a vast number of business and entrepreneurship podcasts scattered across the internet today.

5 Hobbies To Maximize Your Entrepreneurial Drive

5 Hobbies To Maximize Your Entrepreneurial Drive

Entrepreneurs are a special breed of person. They’re go-getters, risk-takers and dreamers. Yet, even the most driven entrepreneur needs to take a break from time to time. Spending every second of your day on your business is stressful, and you will lose your drive very soon. If you want to stay energetic and ready to take on new challenges at work, hobbies are what you need.